Michael Emig

机构：Affimed Therapeutics (Germany) · ORCID：0009-0001-3775-7037

发表论文 107 篇 · 总被引 5763 次 · h-index 21

代表论文

• Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial (2025 · Nature Medicine · 被引 68)
• First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors (2025 · Clinical Cancer Research · 被引 24)
• Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results (2023 · Blood · 被引 21)
• A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas (2024 · Clinical Cancer Research · 被引 20)
• Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC). (2024 · Journal of Clinical Oncology · 被引 12)
• AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE) (2023 · Blood · 被引 12)